We consider the analysis of clinical trials that involve randomization to an active treatment (T = 1) or a control treatment (T = 0), when the active treatment is subject to all-or-nothing compliance. We compare three approaches to estimating treatment efficacy in this situation: as-treated analysis, per-protocol analysis, and instrumental variable (IV) estimation, where the treatment effect is estimated using the randomization indicator as an IV. Both model-and method-ofmoment based IV estimators are considered. The assumptions underlying these estimators are assessed, standard errors and mean squared errors of the estimates are compared, and design implications of the three methods are examined. Extensions of the methods to include observed covariates are then discussed, emphasizing the role of compliance propensity methods and the contrasting role of covariates in these extensions. Methods are illustrated on data from the Women Take Pride study, an assessment of behavioral treatments for women with heart disease.
Introduction
Randomized clinical trials that compare treatments are generally straightforward to analyze, but the analysis and interpretation is complicated when individuals do not comply with their assigned treatments. The gold-standard analysis of such trials in drug approval processes is intention to treat (ITT), where individuals are classified in treatment comparisons according to their assigned treatments, regardless of whether they complied with the treatment. ITT analysis preserves the benefits of randomization, and it provides valid measures of the effect of treatment assignment, sometimes called treatment effectiveness. The analysis is less compelling for estimating treatment efficacy, the effectiveness of a treatment when it is in fact taken.
Simple approaches to estimating treatment efficacy are astreated (AT) analysis, where participants are classified according the treatment actually received, and per-protocol (PP) analysis, which restricts analysis to participants who comply with the assigned treatment. These analyses estimate treatment efficacy, because they classify participants according to received treatment, but they are subject to selection bias, in that participants who comply with a treatment may be a biased sample of participants randomized to that treatment. The bias may be reduced by adjustment for covariates, but it remains a concern. Thus much current clinical trial practice for estimating efficacy involves an unappealing choice between ITT analysis, which is protected from bias by randomization but is really estimating effectiveness, and PP and AT analyses, which measure efficacy but are potentially biased by treatment noncompliance.
Another more recent approach to estimating efficacy treats the randomization as an instrumental variable (IV), in economic parlance. In simple terms the IV estimator corrects the ITT estimator for noncompliance, based on certain assumptions about the outcomes for noncompliers under both treatments. This approach yields a direct estimate of treatment efficacy, and is protected from selection bias by the randomization. On the other hand, it does require certain assumptions to be valid, and it also yields estimators with potentially high variance, particularly if the treatment compliance rate is low. Model-based versions of the IV estimator have been proposed that are potentially more efficient, although they make stronger distributional assumptions.
This article has two objectives. First, we provide a sideby-side comparison of the PP, AT, and IV estimators in the situation with no covariates. Two key ideas here are the definition of a causal effect of an active treatment as the difference in hypothetical outcomes under that treatment and a control treatment (Rubin, 1974 (Rubin, , 1977 (Rubin, , 1978 ; and principal stratification, where individuals are stratified according to the values of the posttreatment variable under both treatments, rather than simply under the treatment actually observed (Frangakis and 
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C 2008, The International Biometric Society Rubin, 2002) . The latter paper generalized the application of the potential outcomes framework in the compliance setting (Baker and Lindeman, 1994; Angrist, Imbens, and Rubin, 1996 , henceforth denoted as AIR) to any postrandomization variable. White (2005) adopts a similar framework in arguing for IV over PP analysis in the context of randomized trials. We include AT in our analysis, provide a more overt discussion of the contrasting assumptions of the methods, and compare their precisions and mean squared errors (MSEs). Second, we discuss and compare the role of covariates, and in particular compliance propensities proposed in this article, in improving the performance of the PP, AT, and IV estimators. We show that covariates can reduce bias and weaken the assumptions for PP and AT estimation, but not for ITT or IV estimation; however, they can improve precision for all the methods. We propose covariate-adjusted IV estimators. Finally we outline extensions to more general settings.
A subset of the data from the "Women Take Pride" (WTP) study, a behavior cardiovascular intervention study (Janevic et al., 2003) , is used to compare the various estimators of treatment efficacy. Participants are older women with heart disease, and the intervention consists of 6 weekly classes to groups of six to eight women, where strategies for managing the disease are developed. Compliance is defined here as attendance at least one class, and hence the analysis does not distinguish between women who fully comply and women who partially comply with treatment-see Baker (2000) for more discussion of this issue. We compare subjects randomized to this treatment group (R = 1, n = 190) with subjects randomized to a control "usual care" treatment (R = 0, n = 184) on one of the main study outcomes. We apply the IV, AT, and PP methods to the WTP study without and with covariates. We discuss the underlying assumptions of these methods in this study, and note that the assumptions for estimating efficacy that are suitable for clinical trials, such as the exclusion restriction (ER) that is required by the IV, might not hold for behavior intervention studies, which are often unblinded.
Estimation of Treatment Efficacy: The Case of No Covariates

Estimands of Treatment Efficacy
We consider randomized studies involving random assignment to an active treatment (R = 1) and a control treatment (R = 0). We assume the treatments are subject to all-or-nothing compliance (Baker, 1997) , so that the actual treatment received (say T(R)) can differ from the treatment assigned (R). Specifically, we assume that the population can then be divided into three groups: never-takers (C = n), who take the control treatment whether they are assigned to the control or active treatment (T (1) = T (0) = 0), compliers who take the treatment they are assigned (C = c) (T (R) = R), and always-takers (C = a), who take the active treatment whether assigned the active or control treatment (T (1) = T (0) = 1). We assume that there are no defiers who take the opposite treatment to that assigned. This is also called the monotonicity assumption. We make the stable unit-treatment value assumption (SUTVA; Rubin, 1978) , which implies that compliance and outcomes for individuals are not affected by the assignments and outcomes of other individuals in the sample (AIR). It is justified in the WTP study, because individuals given the control treatment did not have access to the classes in the intervention arm.
We call C principal compliance, because it is a special case of principal stratification where the posttreatment variable is compliance; subjects are classified by their compliance under both treatments (Frangakis and Rubin, 2002) . Principal compliance differs from observed compliance, which concerns only whether a participant complied with the assigned treatment. Observed noncompliers in the treatment group are never-takers (C = n), observed compliers in the treatment group are compliers or always-takers (C = c or a), observed noncompliers in the control group are always-takers (C = a), and observed compliers in the control group are compliers or never-takers (C = c or n). Thus C is only partly observed. Because it is unaffected by the treatment assigned, it can be used as a stratification variable in treatment comparisons, if the missing data problem can be solved. Table 1A shows a classification of the population by R and C, assuming a proportion α of the population is assigned to the treatment, and population proportions π n , π c , π a of never takers, compliers, and always takers, respectively. The entries reflect independence of R and C, which is a consequence of random treatment assignment.
Consider now an outcome variable Y, and let μ r j denote the mean of Y when assigned R = r (r = 0, 1) for the subpopulation with C = j, (j = n, c, or a); letȳ r j denote the corresponding sample mean, and m rj the corresponding sample size. Table 1B displays population means of Y, with square parentheses when corresponding sample quantities are not observed. The observed sample counts and means are shown in Table 1C . Because there are six cell means in Table 1B , and only four observed means, two restrictions on the means are needed to just identify the model. See White (2005) for a similar presentation of the data.
An ITT estimate in this setting is:
It is protected from selection bias by the randomization, and it measures treatment effectiveness, the causal effect of assigning the treatment without regard to compliance. It arguably does not provide a satisfactory estimate of efficacy, that is, the effect of the treatment itself, because a treatment that is not taken cannot be expected to be effective. We present ITT estimates here for completeness, but focus on other approaches to estimating efficacy that use compliance information. Two estimands of treatment efficacy have been considered (Robins, 1989; Robins and Greenland, 1996; Imbens and Rubin, 1997b) . The complier-average causal effect (CACE) is the average treatment effect (ATE) in the subpopulation of principal compliers:
(AIR). The ATE is defined as the difference in mean outcome if all individuals had been assigned and complied with the treatment (T = 1) and the mean if all individuals had been assigned and complied with the control treatment (T = 0). The ATE requires assumptions about the treatment outcome for noncompliers, in the counterfactual event that they had complied with the treatment. Whether this counterfactual 
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C. Observed means (sample counts)
event is meaningful arguably depends on context. For example, noncompliance to a behavioral treatment such as an exercise regime might plausibly be changed by increased motivation, as might occur if evidence of success of the treatment becomes widely known. On the other hand, if noncompliance to a drug is the result of intolerable side effects, then compliance may require a reformulation of the drug to remove the side effects. This may change the properties of the drug, and estimation of the ATE is consequently more speculative. In the absence of covariates, the ATE and CACE are the same if the ATE is the same for compliers as for noncompliers if they had in fact complied. When this assumption does not hold, the ATE and CACE differ, but additional information is needed to estimate the difference. In the case where covariate information is available, the usual additional assumption to identify the ATE is that the ATE is the same for compliers and noncompliers within strata defined by the covariates. The CACE and ATE are then the same within strata, but the overall CACE weights the stratum effects by the covariate distribution of compliers, and the overall ATE weights the stratum effects by the covariate distribution of compliers and noncompliers. This difference is likely to be minor in many applications. We focus here on the CACE, in order to avoid the need for assumptions about counterfactual conditions. Bang and Davis (2007) compare estimators of the ATE by simulation.
The Assumptions of AT, PP, and IV Estimators
The quantityȳ 1c −ȳ 0c directly estimates the CACE in equation (2), butȳ 1c andȳ 0c are not observed, and additional assumptions are needed to identify the estimate. One possibility is to assume
which asserts that the mean outcome under the control treatment is the same for compliers and never-takers ("no compliance effect for controls," or NCEC), and the mean outcome under the active treatment is the same for compliers and always-takers ("no compliance effect for treatment," or NCET). Conditions (3) for the means are implied by the conditional independence assumptions
where the symbol ∧ denotes independence. White (2005) calls deviations from these assumptions "selection effects." Under NCEC μ and NCET μ , it is natural to estimate both μ 0c and μ 0n byȳ 0(c +n ) and both μ 1c and μ 1a byȳ 1(c +a ) , yielding the PP estimateδ
of the CACE. The problem is that the underlying NCEC μ and NCET μ assumptions are strong and widely viewed as unacceptable, because compliers and never-takers may differ on various unobserved characteristics related to the outcome under the control treatment, and similarly compliers and alwaystakers may differ on characteristics related to the outcome under the active treatment. White (2005) argues that NCEC μ and NCET μ may be plausible in double-blind prevention trials where the active agent has low rates of adverse events, and noncompliance relates to treatment discontinuation, because treatment discontinuation is relatively unlikely to be related to prognosis. NCEC μ and NCET μ can be weakened by adjusting for known covariates, as discussed Section 4, but they remain strong and questionable assumptions that need to be critically evaluated. A different, potentially more palatable way of identifying the CACE is to note that participants in the subpopulation of never-takers (C = n) are randomly assigned to treatment or control, and in both cases they receive T = 0. Similarly always-takers (C = a) receive T = 1 whether assigned to treatment or control. If outcomes do not depend on the treatment assigned in these two subpopulations (e.g., Baker and Kramer, 2005) , then the ER assumption follows:
The term ER originates in the econometric literature (e.g., AIR), although Greenland (2000) cautions that equation (6) differs from other ERs in that independence is defined within principal compliance strata. The ER implies that the means in Table 1B are such that:
The label ER μ denotes "exclusion restriction for means"; and is weaker than ER because it equates the means rather than the full distribution. The ER assumptions equation (6) or (7) are generally considered more plausible than NCEC and NCET, but they remain assumptions, because the outcome may be affected by whether treatment or control is assigned even though the resulting treatment remains the same, particularly in trials of behavioral interventions. Under ER or ER μ , y 1n is an unbiased estimate of both μ 0n and μ 1n , andȳ 1a is an unbiased estimate of both μ 0a and μ 1a . These estimates lead to the following estimate of the CACE, which is consistent under ER or ER μ because the numerator and denominator are unbiased estimates of their respective estimands:
whereπ a = m 0a /m 0+ andπ n = m 1n /m 1+ estimate the proportions of always-takers and never-takers. Equation (8) is sometimes termed the IV estimate, because it is has the form of an IV estimate with the randomization indicator as the instrument. Because under ER the treatment effect is zero for the always-takers and never-takers,δ IV inflates the ITT estimateȳ 1+ −ȳ 0+ by the estimated proportion 1 −π a −π n of compliers (Baker and Lindeman, 1994 ; AIR). Suppose we assume NCEC μ , NCET μ , and ER μ simultaneously:
or the corresponding conditional independence assumptions NCEC + ER, NCET + ER. The natural estimates of μ 0 and μ 1 pool the data for all cases according to treatment received, yielding the AT estimator of the CACE:
To summarize, the NCEC/NCET assumptions lead toδ PP , the ER assumption leads toδ IV and the combined NCEC/NCET and ER assumptions lead toδ AT . Note that all these estimators are moment-based estimators and the underlying assumptions for consistency only require assumptions about the cell means, not the full distributions. In particular, the IV estimate does not require an assumption of homogeneous treatment effects, under ER and the assumption of monotonicity discussed in Section 2.1. (cf. Brookhart and Schneeweiss, 2007) The choice between the estimators rests largely on the perceived validity of their underlying assumptions, although the precision of the estimates may also play a secondary role.
Precision of the AT, PP, and IV Estimators under the ER Assumption
Because the ER assumption is often plausible, we compare biases and variances of the estimates under that assumption. Under these conditions, the large-sample biases of the ITT, ER, PP, and AT estimates for the CACE are B(δ
, where Δ 0 = (μ 0c − μ 0n ) and Δ 1 = (μ 1c − μ 1a ). Thus IV is unbiased, ITT is attenuated even when NCEC and NCET hold, and the bias of PP and AT depend on the relative sizes of Δ 0 and Δ 1 .
Large sample variances of the estimates are obtained by expressing them in the form g(ȳ 1(c +a ) ,ȳ 1n ,ȳ 0(c +n ) ,ȳ 0a ,π n ,π a ), where (ȳ 1(c +a ) ,ȳ 1n ,ȳ 0(c +n ) ,ȳ 0a ) are asymptotically independent, and applying the delta method. Because the resulting expressions are complex and not very insightful, we examine variance and root MSE in more detail for the case when π a = 0, that is, there are no always-takers, as in our example. Assuming a constant within-cell variance σ 2 , we obtain
(1 − απ c ) 4
It is sample sizes, and various choices of Δ = Δ 0 /σ. In Figure 1 , where the sample size is small (m = 50), AT has lower or comparable RMSE to IV unless Δ is high (Δ = 2). In Figure 2 , where the sample size is large (m = 250), IV tends to have superior RMSE unless the compliance rate is low or Δ is small or zero. The implication is that the IV estimate becomes an increasingly attractive alternative to the PP and AT estimates as the sample size increases. If one of either NCEC or ER is assumed true, the other assumption can be tested empirically by comparingȳ 10 −ȳ 0+ with zero; because IV and AT both assume ER, one might increase the efficiency of the CACE estimate by choosing AT over IV if this test is not rejected, or the differenceȳ 10 −ȳ 0+ is "small." This approach has most appeal when the compliance rate is low, because in this caseδ IV has substantially higher variance and the power of the test may be reasonable; when compliance is high the utility of the test is compromised by low power. An indirect approach to checking the ER assumption using covariates is discussed in Section 3.
What fraction α of cases should be assigned to the treatment group for optimal efficiency? Differentiating equation (12) with respect to α, the variance ofδ IV is minimized when α = 0.5, that is, an equal allocation of treated and control cases. This is contrary to the intuition that given noncompliance, more cases should be assigned to the treatment group. On the other hand, the PP variance (13) is minimized when α = (1 + π c (1 + Δ 2 π c (1 − π c ))) −1 . This equals 1/(1 + √ π c ) when Δ = 0, which does assign more cases to the treatment group when there is noncompliance.
Model-Based Estimators of the CACE
The high variance of the IV estimator when the compliance rate is low motivates a search for more efficient estimators. Technically all the estimators considered so far can be viewed as method-of-moment estimators under the various assumptions. Another approach to inference is maximum likelihood (ML) estimation based on a model for the joint distribution of Y, R, and C. For example,
where N (μ r j , σ 2 ) denotes a normal distribution with mean μ r j and variance σ 2 , and MNOM (π) denotes a multinomial distribution with probabilities π = (π n , π c , π a ) for never-takers, compliers, and always-takers, respectively. The parameters of this model are identified by restrictions on the means. Specifically, it is easily shown thatδ PP is ML for this model under the NCEC μ and NCET μ assumptions (3), and δ AT is ML under the NCEC μ , NCET μ , and ER μ assumptions (9). The ML estimate under the ER μ restriction (7) (ML-ER, denoted asδ MLER ) differs fromδ IV ; it does not have an explicit form, but can be computed using the expectationmaximization algorithm, treating partially observed values of C as missing data (AIR). The estimateδ MLER is more efficient thanδ IV (Imbens and Rubin, 1997a) , but makes stronger distributional assumptions, and is potentially sensitive to violations of assumptions like constant σ 2 Rubin, 1997a, 1997b; Abadie, 2002) . For binary outcomes Y with a Bernoulli distribution,δ IV is the ML estimate of the CACE, providing the resulting means in Table 1B , which are estimated probabilities for a binary Y, all lie between zero and one (Baker and Lindeman, 1994) .
CACE Estimation of Treatment Efficacy
with Covariates We discuss in this section the choice and role of covariates in improving the AT, PP, and IV estimators. We show that covariates can reduce bias in the AT and PP estimators, but do not reduce bias in the IV estimator, although they can increase precision. We also propose two compliance propensities, and discuss their role in dimension reduction when the set of covariates is extensive.
The AT and PP estimates with no covariates are the estimated coefficients of T in a regression of Y on T, computed using all the cases for AT and cases that take their assigned treatment for PP. Covariates X can be incorporated as covariates in these regressions, and as with covariate adjustments in observational settings, can reduce bias and increase precision. Concerning bias, a correctly specified regression adjustment with covariates X weakens NCEC and NCET in equation (4) to
that is, to an assumption of no compliance effects within strata defined by X. Covariates that are predictive of the outcome also increase precision by reducing the residual variance of the regression of Y on X and T. Effect modification can be modeled by including interactions between X and T.
In observational studies, a popular strategy for robust modeling when there are a number of covariates is to stratify on the propensity to take the treatment given covariates X. In randomized studies with full compliance this strategy is not needed, because the assignment propensity is unrelated to X because assignment is randomized. With noncompliance, randomization is compromised, and propensity methods again have a role. We propose here the use of compliance propensities in adjusting the AT, PP, and IV estimators. Specifically, to limit bias, a function is sought such that if equation (15) is true, then it remains valid with X replaced by coarsened functions of X. By Rosenbaum and Rubin's (1983) theory of propensity scores, NCECX and NCETX imply
respectively, where p n (X) = p(C = n|C = n or c, X) and p a (X) = p(C = a|C = a or c, X) are propensities to be never-takers or always-takers. These compliance propensities are the coarsest functions of X for which equation (16) holds. These propensities can be estimated by computing (a)p * a (X) = p(C = a | X) from a logistic regression of the binary indicator for always-takers among controls, (b)p * n (X) = p(C = n | X) from a logistic regression of the binary indicator for never-takers among those with R = 1; and (c) esti-
. A propensity adjustment then stratifies on bothp n (X) andp a (X). Note that the same propensity scores apply for both AT and PP, because the NCEC and NCET assumptions are shared by both methods. AT also requires the ER assumption, but that is not weakened by the propensity adjustment, as we shall see below.
Covariates do not play a role in bias reduction for the IV method. To see this, suppose the ER assumption (6) is assumed conditional on X, that is
Then in terms of densities, for never-takers:
where the first and last equalities are by definition, and the middle is implied by ER(X) and the randomization of treat-
Thus ER(X) implies ER, and bias from failure of the ER assumption is not reduced by conditioning on the covariates X.
Covariates can be used to increase the precision ofδ IV , however. For a single categorical X with J categories, letδ IV,k = (ȳ 1+k −ȳ 0+k )/(1 −π a k −π n k ) be the IV estimator within the stratum X = k. Let p k be the proportion of cases in stratum k, estimated from the pooled sample. Then a stratified estimate of the proportion of principal compliers in stratum k is
Weightingδ IV,k by this estimated proportion and summing yields the following stratified IV estimator: (18) where the numerator is a stratified version of the ITT estimator, with improved precision when X is predictive of the outcome, and the denominator is a stratified version of the overall compliance rate, with improved precision when X is predictive of compliance. We conjecture that the former of these two components has the greater potential for variance reduction. A natural generalization ofȳ IV | X for a set of categorical and/or continuous X's iŝ
where the summation is over all individuals i in the sample; y r i is the predicted outcome for unit i if randomized to treatment r, computed from a regression of Y on X and R; and π i is the predicted true compliance for unit i, computed from a regression of C on X estimated from the cases assigned to treatment. The latter should be of a form appropriate for a binary outcome, for example logistic or probit regression. Comparisons of equation (18) or (19) with the structural equations approach of Nagelkerke et al. (2000) would be of interest. An alternative to equation (18) or (19) is to compute ML or Bayes' estimates of the CACE given covariates X, using a full model for the distribution of Y and C, given R and X, and treating the unknown principal compliance indicators as missing data (Imbens and Rubin, 1997a; Little and Yau, 1998) . For example, one might assume
where the compliance model for C given R and X is a multinomial logistic model with parameters θ C , and the outcome model for Y given C, R, and X is a linear regression model with regression parameters θ Y and variance σ 2 . In equation (20), π (x i , θ C ) excludes effects involving r i , because treatment assignment is randomized. If the ER (17) is assumed to hold within all subpopulations defined by the covariates, the mean μ
Interactions between C, R, and baseline covariates can be included in the mean function, but then the CACE (21) is no longer unique but varies according to the value of x i . See also Bond, White, and Walker (2007) . The modeling approach yields gains of efficiency over equation (19), but is more vulnerable to model misspecification Rubin, 1997a, 1997b; Abadie, 2002) . More simulations comparing these methods, and extensions of equation (20) that allow the variance σ 2 to vary across the principal strata, would be of interest. Wenoted in Section 2 that the data do not provide direct evidence of the validity of ER or NCEC/NCET. The same comment applies within strata defined by the covariates X. However, if the covariates are good predictors of never-takers in the treatment group, the relationship between propensity to be a never-taker and outcome can be assessed in the control group, and lack of evidence of a relationship might be construed as indirect evidence in favor of the NCEC assumption, subject to the caveat that this analysis misses effects of unmeasured confounders. Specifically, transform the covariates X into the propensity scorep n (X) and covariates Z orthogonal top n (X), and regress Y onp n (X) and Z in the control group. If the coefficient ofp n (X) in this regression is small, this provides some justification for the NCEC assumption, suggesting that PP or AT analysis may be reasonable options. On the other hand if the regression coefficient ofp n (X) is large, estimates likeδ IV orδ MLER that do not require the NCEC assumption may be preferable. A similar analysis can be applied to the NCET assumption for compliers and always-takers.
Application to the Women Take Pride Study
We illustrate the various efficacy estimates with data from the WTP study. As discussed in Section 1, we restrict attention to randomized subjects, and compare women assigned to the group behavioral intervention (R = 1), where intervention classes are taken in a group, with the control "usual care" treatment (R = 0). In this example, individuals assigned to control do not have access to the group treatment, so there are no always-takers, and C reduces to a two-category variable consisting of compliers and never-takers. Table 2A shows the observed counts and means for the outcome "6-minute walk" taken at month 12, measuring the distance in feet an individual can walk in 6 minutes. We exclude 69 of the 190 subjects in the intervention group and 62 of 184 subjects in the control group who drop out before month 12. We assume that drop out is random within each treatment group, after conditioning on any covariates included in the analysis. In the treatment groupπ c = 105/121 = 86% complied with treatment, where compliance is defined here as completion of at least one of the treatment modules. We compare the IV, PP, and AT estimators of intervention efficacy without and with covariates.
As discussed in Section 2, the IV estimator requires the ER assumption, while the PP analysis requires the NCEC assumption and the AT analysis requires the ER + NCEC assumption. In pharmaceutical clinical trials, where treatments are blinded and the efficacy is based on the properties of the drugs, the ER assumption often seems more reasonable than NCEC, so the IV methods are attractive. For behavioral intervention trials, such as the WTP study, it is not clear that ER is superior to NCEC, particularly if outcomes are thought to be affected by the psychological effects of failing to comply with an assigned treatment, because these effects are in play when an individual is assigned to the treatment but not when an individual is assigned to the control. Faced with uncertainty about which assumption is appropriate, one strategy is to compute both PP and IV estimators and assess whether treatment effects are robust to these alternative assumptions.
We first present analyses without covariates. Table 2B shows the estimated cell means from the IV, PP, AT, and ITT methods, and associated standard errors (SEs); the estimated means in italics are those implied by the assumptions of each method. Note that the ITT estimate is smaller than the others because it is attenuated, and it has the smallest SE. The estimates of the CACE from the other three methods differ somewhat, although not in relation to the SEs, and the PP and AT estimates are statistically significant at the 0.05 alpha level. The SEs order as described in Section 2.3, with relatively small differences because the compliance rate is quite high in this application. The t-test for the combined NCEC + ER assumptions compares the mean for controls (748.90) with the mean for treatment noncompliers (694.12), not statistically significant even though the difference in means is quite substantial. This illustrates the low power of the test when the compliance rate is high.
We next include the following covariates in our analysis of the WTP data: age, employment, and symptom impact profile (SIP) physical score, which measures a subject's physical functioning (Janevic et al., 2003) . The ML estimate of the CACE for the data without adjusting for covariates iŝ δ MLER = 109.78, closeto the IV estimate ofδ IV = 108.76 in Table 2 . It has a slightly lower SE (61.28 versus 65.53). Table 3 shows the results of fitting a model of form (20) to the data from the WTP study. Block (1) shows the coefficients for the outcome model, with the CACE being the compliance × treatment interaction. Block (2) shows coefficients from the compliance model. The covariate-adjusted ML estimate of the CACE from this model is 97.20 with a reduced SE, namely 43.73, indicating some improvement in precision from adjusting for the covariates. In addition, women with higher baseline measure tend to have higher 6-minute walk measure at month 12, and older women tend to have lower 6-minute walk measure at month 12. Table 4 summarizes the IV, ML-ER, PP, AT, and ITT estimates both with and without covariate adjustments. ITT, PP, and AT estimates with covariate adjustments are obtained using linear regression adjusting for age, baseline 6-minute walk measurement, and employment status. The IV estimate with covariate adjustments is obtained using equation (19), and baseline variables including employment status and SIP physical scores are used to estimate propensity scoresπ i for each subject. Table 4 shows that covariate adjustment generally improves precision and reduces differences between the methods, except ITT which remains attenuated. The large gain in efficiency may be due to the significant effects of age and baseline measurements on the outcome of interest. We note in particular that covariate adjustment of IV based on equation (18) results in 50% reduction in estimated SE, and a significant treatment effect. The results suggest that compliers performed better under treatment rather than under control for this outcome.
Discussion
We have compared a variety of methods for estimating efficacy in randomized trials for a control and active treatment, when there is all-or-nothing noncompliance. In practice, the choice of methods depends on various factors, effect sizes relative to between-subject variability of the outcome measure, sample size, and differences in characteristics of compliers and noncompliers. The choice also depends on the plausibility of the different modeling assumptions and the trade-off between efficiency and robustness. If NCEC/NCET or NCEC/NCET + ER given a set of covariates can be believed, and regressions on the covariates are correctly specified, then AT can be dramatically more efficient than IV. On the other hand, the IV estimate of the CACE under ER is robust against misspecification of our regression model or false belief in NCEC. Thus, it may be wise to compute and compare all the estimates to assess sensitivity of answers to the choice of method.
Many generalizations and extensions of these methods are possible. Extensions that require more restrictions to identify the parameters include the case where partial compliance is modeled (Goetghebeur and Molenberghs, 1996) , or there are more than two treatments, such as two active treatments and a control treatment that are assumed to apply to noncompliers. CACE estimation in trials involving a control group and more than one treatment groups is more complicated, with more principal compliance categories and more complicated identifiability assumptions. Results on this case will be reported elsewhere. Another extension is to joint models for noncompliance and missing data-for simplicity we confined our analyses of 12-month WTP data to completers. For some approaches to this issue see Frangakis and Rubin (1999) and Peng, Little, and Raghunathan (2004) .
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